GGrantIndex
← Leaderboards

David J Davido

University Of Kansas Lawrence

$2,765,043
Attributed
$3,895,246
Total exposure
10
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $641.1K · FY200725
$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$3,895,246 · 10

By mechanism

R21$2,523,187 · 6
R01$1,253,816 · 1
P20$118,243 · 3

Top collaborators

Most similar at University Of Kansas Lawrence

Same institution · by research overlap

Others in their field

Top investigators on “Mediating

Research focus

MediatingInfectionSimplexvirusProteinsViralVirusCellsPreventVirus ReplicationViral ProteinsVirus DiseasesMolecularPlayGene ExpressionEventInnovationViral GenesRecurrenceLatent InfectionLytic PhaseUbiquitin-Protein LigaseGenital SystemBlindnessMutant

Grant awards (19)

Determining the role of PARP14 in restricting HSV-1 replication$411,499
R21 · FY2025 · AI · contact PI
Role of ICP0 Dimerization in Herpes Simplex Virus Pathogenesis$229,624
R21 · FY2025 · AI · contact PI
Role of ICP0 Dimerization in Herpes Simplex Virus Pathogenesis$200,782
R21 · FY2024 · AI · contact PI
Identifying functional targets of HSV-1 ICP0-directed degradation$183,589
R21 · FY2021 · AI · contact PI
Identifying functional targets of HSV-1 ICP0-directed degradation$221,712
R21 · FY2020 · AI · contact PI
Identification of novel HSV-1 ICP0 E3 ligase targets by mass spectrometry in neurons$192,204
R21 · FY2019 · NS
Identification of novel HSV-1 ICP0 E3 ligase targets by mass spectrometry in neurons$245,495
R21 · FY2018 · NS
Dissecting the Contribution of Viral Genetic Variation to HSV-1 Neuropathogenesis$226,223
R21 · FY2017 · NS
Dissecting the Contribution of Viral Genetic Variation to HSV-1 Neuropathogenesis$201,337
R21 · FY2016 · NS
Viral and host responses to HSV infection$274,307
R01 · FY2010 · AI · contact PI
Improving Vaccine Safety and Efficacy to Control Primary HSV-1 Infections$209,309
R21 · FY2010 · EY
Viral and host responses to HSV infection$277,263
R01 · FY2009 · AI · contact PI
Improving Vaccine Safety and Efficacy to Control Primary HSV-1 Infections$201,413
R21 · FY2009 · EY
Viral and host responses to HSV infection$91,589
R01 · FY2009 · AI · contact PI
Viral and host responses to HSV infection$277,440
R01 · FY2008 · AI · contact PI
INBRE: KU-L: VIRAL AND HOST RESPONSES TO HSV INFECTION$43,371
P20 · FY2008 · RR · contact PI
Viral and host responses to HSV infection$333,217
R01 · FY2007 · AI · contact PI
INBRE: KU-L: VIRAL AND HOST RESPONSES TO HSV INFECTION$53,936
P20 · FY2007 · RR · contact PI
IDENTIFYING TARGETS OF E3 UBIQUITIN LIGASES:ROLE IN BRCA1-MEDIATED BREAST CANCER$20,936
P20 · FY2007 · RR · contact PI